OBJECTIVE: Fibroblast growth factor-21 (FGF-21) has recently been characterized as a potent metabolic regulator, but its pathophysiologic roles in humans remain unknown. This study aimed to investigate the effects of rosiglitazone on plasma FGF-21 levels in patients with type 2 diabetes mellitus (T2DM). DESIGN AND METHODS: Thirty patients with new-onset T2DM (nT2DM), 34 type 2 diabetic patients with poor glycemic control (pT2DM) after the treatment with single hypoglycemic agent metformin, and 30 sex- and age-matched normal glycaemic controls (NGT) participated in the study. The pT2DM group was treated with rosiglitazone for 12 weeks. Plasma FGF-21 levels were measured with a RIA. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed. RESULTS: Fasting plasma FGF-21 levels were higher in nT2DM and pT2DM groups than in the control (1.81+/-0.64 vs 1.87+/-0.63 vs 1.52+/-0.61 microg/l, P<0.05), but there was no difference between nT2DM and pT2DM groups. Fasting plasma FGF-21 levels were decreased significantly in pT2DM group after the treatment with rosiglitazone compared with pre-treatment (1.59+/-0.63 vs 1.87+/-0.64 micro/l, P<0.05). In all diabetic patients, multiple regression analysis showed that HbA1c, fasting insulin, and homeostasis model assessment-insulin resistance index were independently associated with plasma FGF-21 levels. CONCLUSIONS: In pT2DM patients, plasma FGF-21 levels are increased, but significantly decreased after the treatment with rosiglitazone on top of ongoing metformin therapy. These data suggest that rosiglitazone may play a role in lowering FGF-21 levels in T2DM patients.
OBJECTIVE:Fibroblast growth factor-21 (FGF-21) has recently been characterized as a potent metabolic regulator, but its pathophysiologic roles in humans remain unknown. This study aimed to investigate the effects of rosiglitazone on plasma FGF-21 levels in patients with type 2 diabetes mellitus (T2DM). DESIGN AND METHODS: Thirty patients with new-onset T2DM (nT2DM), 34 type 2 diabeticpatients with poor glycemic control (pT2DM) after the treatment with single hypoglycemic agent metformin, and 30 sex- and age-matched normal glycaemic controls (NGT) participated in the study. The pT2DM group was treated with rosiglitazone for 12 weeks. Plasma FGF-21 levels were measured with a RIA. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed. RESULTS: Fasting plasma FGF-21 levels were higher in nT2DM and pT2DM groups than in the control (1.81+/-0.64 vs 1.87+/-0.63 vs 1.52+/-0.61 microg/l, P<0.05), but there was no difference between nT2DM and pT2DM groups. Fasting plasma FGF-21 levels were decreased significantly in pT2DM group after the treatment with rosiglitazone compared with pre-treatment (1.59+/-0.63 vs 1.87+/-0.64 micro/l, P<0.05). In all diabeticpatients, multiple regression analysis showed that HbA1c, fasting insulin, and homeostasis model assessment-insulin resistance index were independently associated with plasma FGF-21 levels. CONCLUSIONS: In pT2DM patients, plasma FGF-21 levels are increased, but significantly decreased after the treatment with rosiglitazone on top of ongoing metformin therapy. These data suggest that rosiglitazone may play a role in lowering FGF-21 levels in T2DM patients.
Authors: Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Martin Torriani; Steven K Grinspoon; Takara L Stanley Journal: Growth Horm IGF Res Date: 2017-10-07 Impact factor: 2.372
Authors: Ricardo J Samms; Christine C Cheng; Marcel Fourcaudot; Sami Heikkinen; Ahmed Khattab; John Adams; Eugenio Cersosimo; Curtis Triplitt; Curtis Puckett; Kostas Tsintzas; Andrew C Adams; Muhammad A Abdul-Ghani; Ralph A DeFronzo; Luke Norton Journal: Am J Physiol Endocrinol Metab Date: 2022-06-20 Impact factor: 5.900
Authors: Andrew C Adams; Tamer Coskun; Christine C Cheng; Libbey S O Farrell; Susan L Dubois; Alexei Kharitonenkov Journal: Mol Metab Date: 2013-05-29 Impact factor: 7.422
Authors: Paul A Dutchak; Takeshi Katafuchi; Angie L Bookout; Jang Hyun Choi; Ruth T Yu; David J Mangelsdorf; Steven A Kliewer Journal: Cell Date: 2012-02-03 Impact factor: 41.582